TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ABUS

Arbutus Biopharma Corp

Healthcare · Biotechnology

5.00$ -1.2% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Arbutus Biopharma Corp (ABUS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 61.9% of the shares are freely tradable; institutional investors hold 71.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 71.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 20.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 61.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 14.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 198Mio.

Largest Shareholders

Institutions

Institutions ABUS
Name Stake (%) Shares Change (%) Date
Morgan Stanley - Brokerage Accounts 13.07 25,891,480 -3.0 03/31/2026
Two Seas Capital LP 9.37 18,557,543 +47.4 03/31/2026
Whitefort Capital Management, LP. 7.97 15,794,261 +5.8 06/30/2026
BlackRock Inc 6.55 12,966,946 -0.7 03/31/2026
Vanguard Capital Management, LLC 3.38 6,688,911 +0.0 03/31/2026
Rubric Capital Management LP 3.34 6,626,389 +320.6 03/31/2026
State Street Corp 3.20 6,342,510 +7.4 03/31/2026
Barclays PLC 2.18 4,316,095 +1,110.1 03/31/2026

Funds

Funds ABUS
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.54 5,034,547 +0.0 07/31/2026
iShares Russell 2000 ETF 2.04 4,048,497 -0.6 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?